Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Study Details
Study Description
Brief Summary
This trial is being conducted as a possible treatment for lung cancer with a specific change in the KRAS gene.
The drugs involved in this study are:
-
Palbociclib
-
Binimetinib
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1/Phase 2 |
Detailed Description
This research study is a Phase I/II clinical trial. Participants are being asked to participate in the Phase I portion of the study. A Phase I clinical trial tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies. "Investigational" means that the intervention is being studied.
Palbociclib is an oral drug which has been shown to stop the cell cycle, which is the way a cell initiates growth. Binimetinib is also an oral drug which stops a signal that a cell receives, instructing it to grow. By putting these two drugs together the investigators hope that it will have a greater affect on cancer growth than either drug alone. The FDA (the U.S. Food and Drug Administration) has not approved binimetinib as a treatment for any disease. The FDA has not approved palbociclib for use in lung cancer but it has been approved for other cancer types.
The purpose of this study is to:
-
Test the combination of these two drugs, Palbociclib and Binimetinib, in order to determine a safe and tolerable dose of the combination
-
Determine the response rate of the combination
-
Further evaluate the safety and side effect profile for the combination of palbociclib and binimetinib.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Binimetinib Combine with Palbociclib Phase 1 Palbociclib will be administered orally once daily Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle Binimetinib will be administered orally twice daily Patients will be dosed with Binimetinib continuously through the four weeks per cycle |
Drug: Binimetinib
Binimetinib is also an oral drug which stops a signal that a cell receives, instructing it to grow.
Other Names:
Drug: Palbociclib
It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6
Other Names:
|
| Experimental: Binimetinib Combine with Palbociclib Phase 2 Palbociclib will be administered orally once daily Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle Binimetinib will be administered orally twice daily Patients will be dosed with Binimetinib continuously through the four weeks per cycle |
Drug: Binimetinib
Binimetinib is also an oral drug which stops a signal that a cell receives, instructing it to grow.
Other Names:
Drug: Palbociclib
It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6
Other Names:
|
| Experimental: Binimetinib Phase 2 Binimetinib will be administered orally twice daily Patients will be dosed with Binimetinib continuously through the four weeks per cycle |
Drug: Binimetinib
Binimetinib is also an oral drug which stops a signal that a cell receives, instructing it to grow.
Other Names:
|
| Experimental: Palbociclib Phase 2 Palbociclib will be administered orally once daily Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle |
Drug: Palbociclib
It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Maximum Tolerated Dose [2 years]
A standard 3+3 design will be implemented to discover the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of the combination of study drugs. A dose will be declared the MTD if zero or 1 patient out of 6 experience a dose limiting toxicity (DLT) at the highest dose level below the maximally administered dose. This is generally the Recommended Phase 2 dose- RP2D
- Safety and tolerability of Palbocilib and Binimetinib [2 Years]
Toxicities will be graded using version 4.0 of the NCI Common Terminology Criteria for Adverse Events (CTCAE).
- progression free survival [4 months]
Determine the proportion of patients who are alive and progression-free at 4 months in the binimetinib, palbociclib and combination arms.
Secondary Outcome Measures
- Pharmacokinetics [15 days]
The pharmacokinetic properties-Cmax maximum plasma concentration for the combination of palbociclib and PD-0325901 will be evaluated utilizing serial blood draws on cycle 1 day 1 and a steady state trough level drawn on cycle 1 day 15.
- Target engagement of palbociclib and binimetinib [2 years]
Confirm target engagement of palbociclib and binimetinib in pre- and on-treatment tumor biopsies from patients enrolled to an MTD expansion cohort.
- Objective Response [2 years]
Determine the best objective response rate, as determined by RECIST 1.1, of the combination of palbociclib and binimetinib, palbociclib alone and binimetinib alone in patients with advanced KRAS mutant NSCLC.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participants must have histologically confirmed advanced NSCLC (with a confirmed KRAS mutation via any CLIA-certified method) for which curable treatment modalities are not an option
-
Part I Dose Escalation: Participants are required to have measurable disease per RECIST 1.1 within 4 weeks of study entry
-
MTD Expansion and Part II: Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral CT scan. See section 10 for the evaluation of measureable disease.
-
Age ≥ 18 years. Because no dosing or adverse event data are currently available in participants < 18 years of age, children are excluded from this study
-
Participants are permitted to have any number of prior therapies prior to enrollment
-
ECOG performance status < 2 (see Appendix A).
-
Participants must have normal organ and marrow function as defined below:
-
Absolute neutrophil count > 1,500mm3
-
Hemoglobin > 9 g/dL
-
Platelets > 100,000/mcL
-
Total bilirubin < 2 X institutional upper limit of normal (ULN)
-
AST (SGOT)/ALT (SGPT) < 2.5 X ULN -OR-
-
AST (SGOT)/ALT (SGPT) < 5.0 X ULN if hepatic metastases are present
-
Creatinine < 1.5 X the institutional ULN -OR-
-
Calculated creatinine clearance (determined as per Cockcroft-Gault) > 50 mL/min
-
The effects of palbociclib and binimetinib on the developing human fetus are not fully known. For this reason, women of child-bearing potential and men must agree to use adequate contraception (combination hormonal and barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days after discontinuation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
-
Ability to understand and the willingness to sign a written informed consent document.
-
The availability of archival tissue to evaluate retrospectively the participant's Rb status. The requirement is a minimum of 5 unstained slides with each tissue cut measuring 4 microns in width. Ideally 15 slides will be requested. Patients without available archival tissue may be enrolled at the discretion of the principal investigator.
-
Patients must have recovered to ≤ Grade 1 in terms of toxicity from prior treatments (excluding neuropathy which can be ≤ Grade 2, and alopecia).
-
MTD Expansion: Patients must be willing to undergo pre- and on-treatment tumor biopsies. Patients are exempt from this requirement if, in the opinion of the investigator, the biopsy procedure would pose a significant risk or if they have only pulmonary metastatic disease.
-
Patients must be able to take oral medications.
-
Patients must have adequate cardiac function, defined as:
-
Left ventricular ejection fraction (LVEF) > 50% as determined by echocardiogram or multigated acquisition scan (MUGA).
-
QTc < 480 msec.
Exclusion Criteria:
-
Participants who have had chemotherapy, radiotherapy, or major surgery within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study.
-
Participants receiving any other study agents concurrently with the study drugs.
-
Participants with symptomatic brain metastases that require chronic steroids. Patients with a history of brain metastases are permitted to enroll as long as they have been treated, are off of steroids, and have been stable for a minimum of one month on imaging.
-
MTD Expansion: Patients currently taking anticoagulants and who cannot safely hold the medication to facilitate pre and on-treatment tumor biopsies are excluded from participation.
-
Concurrent use of strong CYP3A4 inhibitors/inducers is prohibited due to drug-drug interactions with palbociclib. Moderate CYP3A4 inhibitors/inducers should be used with caution (see Appendix C).
-
Part I Dose Escalation: Concurrent use of proton-pump inhibitors (PPIs) is prohibited.
-
Uncontrolled intercurrent illness including, but not limited to:
-
ongoing or active infection requiring systemic treatment
-
symptomatic congestive heart failure
-
cardiac arrhythmia
-
psychiatric illness/social situations that would limit compliance with study requirements
-
hypertension, defined as systolic blood pressure > 160 mmHg despite medical management
-
myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting < 6 months prior to screening
-
History of QT syndrome, Brugada syndrome, known history of QTc prolongation, or Torsades de Pointes.
-
History of Gilbert's syndrome.
-
History of neuromuscular disorders that are associated with elevated CK (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).
-
History of other malignancy which could affect compliance with the protocol or interpretation of results. History of curatively treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix are allowed. Subjects with a malignancy that has been treated with curative intent will also be allowed if the malignancy has been in remission without treatment for ≥ 2 years prior to Cycle 1, Day
- Subjects with localized prostate cancer that has been treated with curative intent will be allowed
-
Patients planning to embark on a new strenuous exercise regimen after the first dose of study treatment.
-
History of a malabsorption syndrome or uncontrolled nausea, vomiting, or diarrhea that may interfere with the absorption of oral study medication in the opinion of the investigator.
-
Pregnant women are excluded from this study because the study agents have the potential for teratogenic or abortifacient effects. As there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with the study agents, breastfeeding must be discontinued if the mother is treated.
-
Part II: Individuals with a history of a different malignancy are ineligible except for the following circumstances:
-
They have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy.
-
Individuals with the following cancers are eligible if diagnosed and curatively treated within the past 5 years: cervical cancer in situ, and basal or squamous cell carcinoma of the skin.
-
Known HIV-positive individuals on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.
-
Patients with known active hepatitis B and/or active hepatitis C infection.
-
Evidence of visible retinal pathology on screening ophthalmologic examination that places the participant at an unacceptable risk for retinal vein occlusion (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity, etc.).
-
History of retinal degenerative disease.
-
Presence of neurosensory retinal detachment, retinal vein occlusion (RVO), or neovascular macular degeneration on screening ophthalmologic exam.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Dana Farber Cancer Institute | Boston | Massachusetts | United States | 02215 |
| 2 | Massachusetts General Hospital | Boston | Massachusetts | United States | 02215 |
Sponsors and Collaborators
- Dana-Farber Cancer Institute
- Pfizer
- Array BioPharma
Investigators
- Principal Investigator: Geoffrey Shapiro, MD, PhD, Dana-Farber Cancer Institute
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 16-531